No profile data available.
Firebrick Pharma Limited (FRE.AX) is an essential consumer products company in the standard hygiene product manufacturers industry, based in Melbourne, Australia.
Asia was its largest region in fiscal year 2025, with 74% of revenue. Its market capitalization was 8.33 million AUD as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2025; market data as of October 9, 2026.
Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
Asia: 74% of revenue by region in fiscal year 2025, followed by North America (22%).
8.33 million AUD as of October 9, 2026.
Listed companies of a similar size in the same industry (standard hygiene product manufacturers) include McPherson's Limited (MCP.AX), EVE Health Group Limited (EVE.AX), Prestal Holdings Limited (PTL.AX).